Macrophage inhibitory cytokine 1: A new prognostic marker in prostate cancer

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6658-6664

  Brown, David A ^a   Lindmark, Fredrik ^b   Stattin, Pär ^b   Bälter, Katarina ^c   Adami, Hans Olov ^c,d   Zheng, Sigun L ^e   Xu, Jianfeng ^e   Isaacs, William B ^f   Grönberg, Henrik ^c   Breit, Samuel N ^a   Wiklund, Fredrik E ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e WAKE FOREST UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FOLLOW UP; GENOTYPE; GLEASON SCORE; HAPLOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70350733627     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3126     Document Type: Article

References (32)

1. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-2719 (Pubitemid 38725420)
2. Schraudenbach P, Bermejo CE. Management of the complications of radical prostatectomy. Curr Urol Rep 2007;8:197-202.
3. Partin AW, Piantadosi S, Sanda MG, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45:831-838
4. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-125
5. KattanMW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90:766-771 (Pubitemid 28259189)
6. Welsh JB, Sapinoso LM, Kern SG, et al. Largescale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410-3415
7. Bauskin AR, Brown DA, Junankar S, et al. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res 2005;65:2330-2336 (Pubitemid 40490143)
8. Brown DA, Stephan C, Ward RL, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006;12:89-96. (Pubitemid 43166181)
9. Johnen H, Lin S, Kuffner T, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1. Nat Med 2007;13:1333-1340 (Pubitemid 350073601)
10. Lindmark F, Zheng SL, Wiklund F, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004;96:1248-1254 (Pubitemid 39232716)
11. Varenhorst E, Garmo H, Holmberg L, et al. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 2005;39:117-123
12. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265 (Pubitemid 40202029)
13. Brown DA, Bauskin AR, Fairlie WD, et al. Antibody-based approach to high-volume genotyping for MIC-1 polymorphism. Biotechniques 2002;33:118-20, 22, 24 passim.
14. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995;41: 1115-1120
15. Team. RDC R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2006.
16. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843
17. StataCorp. Stata statistical software: release 9. College Station (TX): StataCorp LP; 2005.
18. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154
19. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293:2095-2101 (Pubitemid 40617061)
20. Klotz LH. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and under-treatment for aggressive disease. Can J Urol 2005;12 Suppl 1:53-7, discussion 101-102
21. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007;99:526-532 (Pubitemid 47073555)
22. Diaz-Martin MA, Traba ML, De La Piedra C, Guerrero R, Mendez-Davila C, De La Pena EG. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma. Scand J Clin Lab Invest 1999;59: 125-132 (Pubitemid 29226401)
23. Nakamura T, Scorilas A, Stephan C, et al. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 2003;88:1101-1104 (Pubitemid 36560783)
24. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88:2919-2926
25. Selander KS, Brown DA, Sequeiros GB, et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 2007;16:532-537
26. Bauskin AR, Brown DA, Kuffner T, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006; 66:4983-4986 (Pubitemid 43852864)
27. Albertoni M, Shaw PH, Nozaki M, et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002;21:4212-4219 (Pubitemid 34753827)
28. Li PX, Wong J, Ayed A, et al. Placental transforming growth factor-β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 over-expression. J Biol Chem 2000;275:20127-20135 (Pubitemid 30441624)
29. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001;59:901-908
30. Ferrari N, Pfeffer U, Dell'Eva R, Ambrosini C, Noonan DM, Albini A. The transforming growth factor-β family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res 2005;11:4610-4619 (Pubitemid 40825652)
31. Lee DH, Yang Y, Lee SJ, et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003;63:4648-4655 (Pubitemid 36951043)
32. Fall K, Stromberg F, Rosell J, Andren O , Varenhorst E. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008;42:352-357